Consistent with this is a recent report indicated that early subcutaneous IFN-β administered up to three times (with ribavirin) in the first seven days after diagnosis of COVID-19 was associated with faster virus clearance and substantial clinical improvement with shorter hospital stays63. Here, IFNB1 is linked to COVID-19.